EDSA Stock — Edesa Biotech Inc.: Cash, EV, Pipeline

What they do

We are a biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our approach is to acquire, develop and commercialize drug candidates based on mechanisms of action that have demonstrated proof-of-concept in human subjects.

Source: 10-K FY2025 via SEC EDGAR

Share price

$2.14

Market cap

$28.9M

Cash

$10.3M

Enterprise value

$18.6M

Balance sheet

Cash	$10.3M
Debt	$0.0M
Net cash	$10.3M
Enterprise value	$18.6M
Basic shares	9.6M shares
Fully diluted shares	15.0M shares
Fully diluted market cap	$32.2M
Cash per share	$1.07
Quarterly burn	$3.1M
Cash runway	3.4 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

9.6M

Pre-funded warrants

0.0M

Options

0.4M

RSUs

0.0M

Warrants

0.7M

Converts

0.0M

Conv preferred

4.3M

ESPP reserve

—

FDSO

15.0M

Cap table as of 2026-06-30.

Price history

Loading EDSA daily closes…

Loading price history…

Next catalyst

Cohort C: bevacizumab · Aug 12 - Sep 23 in 21 mo · Phase 2 · Acute Respiratory Distress Syndrome (ARDS); ARDS; ARDS (Acute Respiratory Distress Syndrome)

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Aug 12 - Sep 23 in 21 mo	Cohort C: bevacizumab	Phase 2	Acute Respiratory Distress Syndrome (ARDS); ARDS; ARDS (Acute Respiratory Distress Syndrome)	—
Aug 12 - Sep 23 in 21 mo	Cohort B: paridiprubart	Phase 2	Acute Respiratory Distress Syndrome (ARDS); ARDS; ARDS (Acute Respiratory Distress Syndrome)	—
Aug 12 - Sep 23 in 21 mo	Cohort A: vilobelimab	Phase 2	Acute Respiratory Distress Syndrome (ARDS); ARDS; ARDS (Acute Respiratory Distress Syndrome)	—
Aug 12 - Sep 23 in 21 mo	Cohort A: vilobelimab	Phase 2	Acute Respiratory Distress Syndrome (ARDS); ARDS; ARDS (Acute Respiratory Distress Syndrome)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

EB06

Phase 2 · Active Modality: monoclonal antibody

Target CXCL10

Partnerships Unnamed pharmaceutical development company: exclusive worldwide license to monoclonal antibody Constructs incl. sublicensing rights (Apr 2020; 25-year term from first commercial sale)

Indications

Vitiligo (moderate-to-severe nonsegmental) (Phase 2)

Status note Health Canada approved Phase 2 proof-of-concept study in vitiligo; CMC information being provided to FDA in connection with IND. Manufacturing preparations for planned Phase 2 underway.

Paridiprubart

Phase 3 · Active

Aliases EB05

Target TLR4

Partnerships Government of Canada Strategic Response Fund: up to C$23M partially repayable funding (Oct 2023, amended Sep 2025) for Phase 3 completion, approval submissions, manufacturing scale-up and two non-clinical safety studies

Indications

Acute respiratory distress syndrome (ARDS) (Phase 3)

Status note Phase 3 study in hospitalized ARDS patients reported Oct 2025; being evaluated in an ongoing U.S. government-funded ARDS platform study.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	EB06
Lead indication	Non-Segmental Vitiligo (NSV)
Lead phase	Phase 2
Active trials	0
Collaborator trials	4

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06701656	Phase 2	Recruiting	Collaborator	PPD Development, LP	—	Acute Respiratory Distress Syndrome (ARDS); ARDS; ARDS (Acute Respiratory Distress Syndrome)	—
NCT06701669	Phase 2	Recruiting	Collaborator	PPD Development, LP	—	Acute Respiratory Distress Syndrome (ARDS); ARDS; ARDS (Acute Respiratory Distress Syndrome)	—
NCT06701682	Phase 2	Recruiting	Collaborator	PPD Development, LP	—	Acute Respiratory Distress Syndrome (ARDS); ARDS; ARDS (Acute Respiratory Distress Syndrome)	—
NCT06703073	Phase 2	Recruiting	Collaborator	PPD Development, LP	—	Acute Respiratory Distress Syndrome (ARDS); ARDS; ARDS (Acute Respiratory Distress Syndrome)	—

Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 4 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for PPD Development, LP on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Perceptive Advisors	563,239	no change	0.07%	2026-08-14
Stonepine Capital	456,439	+426,439	2.43%	2026-08-17
Boxer Capital	205,000	+205,000	0.13%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

EDSA — Edesa Biotech Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

EDSA — Edesa Biotech Inc.